Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,036 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K. Matsumoto T, et al. Target Oncol. 2024 Mar;19(2):181-190. doi: 10.1007/s11523-024-01043-2. Epub 2024 Mar 1. Target Oncol. 2024. PMID: 38427280 Free PMC article. Clinical Trial.
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T. Kuboki Y, et al. Among authors: matsumoto t. Lancet Oncol. 2017 Sep;18(9):1172-1181. doi: 10.1016/S1470-2045(17)30425-4. Epub 2017 Jul 28. Lancet Oncol. 2017. PMID: 28760399 Clinical Trial.
Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab.
Matsumoto T, Oda T, Yoshida Y, Kimura S, Himei H, Tsuduki T, Takagi S, Takatani M, Morishita H. Matsumoto T, et al. Int Cancer Conf J. 2019 Dec 6;9(1):28-31. doi: 10.1007/s13691-019-00396-0. eCollection 2020 Jan. Int Cancer Conf J. 2019. PMID: 31950014 Free PMC article.
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii T, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J. Satake H, et al. Among authors: matsumoto t. Oncologist. 2020 Dec;25(12):e1855-e1863. doi: 10.1634/theoncologist.2020-0643. Epub 2020 Aug 3. Oncologist. 2020. PMID: 32666647 Free PMC article. Clinical Trial.
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
Shinozaki K, Yamada T, Nasu J, Matsumoto T, Yuasa Y, Shiraishi T, Nagano H, Moriyama I, Fujiwara T, Miguchi M, Yoshida R, Nozaka K, Tanioka H, Nagasaka T, Kurisu Y, Kobayashi M, Tsuchihashi K, Inukai M, Kikuchi T, Nishina T. Shinozaki K, et al. Among authors: matsumoto t. Int J Clin Oncol. 2021 Feb;26(2):399-408. doi: 10.1007/s10147-020-01811-w. Epub 2020 Oct 23. Int J Clin Oncol. 2021. PMID: 33097971 Free PMC article. Clinical Trial.
Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Satake H, Hashida H, Tanioka H, Miyake Y, Yoshioka S, Watanabe T, Matsuura M, Kyogoku T, Inukai M, Kotake T, Okita Y, Matsumoto T, Yasui H, Kotaka M, Kato T, Kaihara S, Tsuji A. Satake H, et al. Among authors: matsumoto t. Oncologist. 2021 Jul;26(7):e1125-e1132. doi: 10.1002/onco.13816. Epub 2021 May 31. Oncologist. 2021. PMID: 33977607 Free PMC article.
10,036 results
You have reached the last available page of results. Please see the User Guide for more information.